Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DWTX
DWTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DWTX News
Dogwood Therapeutics Reports Q1 Financial Results
May 14 2026
seekingalpha
Dogwood Therapeutics Reports Q1 2026 Financial Results and Pipeline Progress
May 14 2026
Newsfilter
Dogwood Therapeutics to Report Q1 2026 Financial Results on May 14
May 07 2026
Newsfilter
Dogwood Secures SP16 License for Cancer Pain Treatment
Apr 15 2026
Newsfilter
Virios Therapeutics Q4 Financial Overview
Mar 18 2026
seekingalpha
Dogwood Therapeutics Achieves Milestone in HALT-CINP Trial
Feb 02 2026
Newsfilter
Dogwood Therapeutics Raises $12.5 Million to Advance Halneuron® Development
Jan 12 2026
Globenewswire
Dogwood Therapeutics Reports Positive Interim Results for Halneuron in Chemotherapy-Induced Neuropathic Pain
Dec 23 2025
NASDAQ.COM
Dogwood Therapeutics (DWTX) Releases Interim Analysis of Halneuron Phase 2b Study
Dec 22 2025
Yahoo Finance
Dogwood Therapeutics Reports Positive Interim Results for Halneuron®; Top-Line Data Expected Q3 2026
Dec 22 2025
Globenewswire
Dogwood Therapeutics Registers 100 Participants in Halneuron Study for Chemotherapy-Induced Pain
Nov 11 2025
Yahoo Finance
Dogwood Therapeutics Obtains Exclusive Global, Royalty-Free License for SP16 Development and Commercialization as a Cancer Pain Treatment in All-Stock Deal Highlighting Commitment to Enhancing Cancer Patient Care
Sep 29 2025
Newsfilter
Dogwood Obtains License to Develop Serpin Pharma's SP16 IV Formulation
Sep 29 2025
NASDAQ.COM
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
Aug 07 2025
Newsfilter
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
Jun 03 2025
Newsfilter
HC Wainwright & Co. Upgrades Dogwood Therapeutics to Buy, Announces $10 Price Target
Apr 23 2025
Benzinga
Show More News
